Partner

901 New York Ave. NW
Washington, DC 20001

+1 202 408 4134

Litigation Star


Jurisdiction:

District of Columbia


Paul Browning, Ph.D., is a first chair litigator focusing on patent litigation and appeals, primarily in the chemical and pharmaceutical areas, including Hatch-Waxman (ANDA) litigation. He has tried cases before judges in various U.S. district courts and has handled arbitrations and mediations. He also advises on patent portfolio strategy with an eye toward success in litigation.


Paul’s broad litigation experience includes taking and cross-examining witnesses at trial, briefing and arguing dispositive motions, drafting appellate briefs, and arguing cases on appeal. He has also managed day-to-day litigation activities in actions involving multiple parties. In addition to his litigation practice, Paul advises clients on a variety of patent matters, including strategic development of their patent portfolios and coordination of prosecution and U.S. and foreign litigation strategy and related proceedings before the Patent Trial and Appeal Board (PTAB).


Paul frequently lectures on various topics in chemical patent law. He designed laser systems and conducted spectroscopy of small molecules while earning master’s and Ph.D. degrees at the University of Chicago.


Paul devotes a portion of his practice to pro bono matters and currently leads Finnegan’s Pro Bono Committee. He represents military personnel seeking enhanced compensation for injuries received while serving in the military, including injuries received in combat. He also represents veterans in cases before the U.S. Court of Appeals for Veterans Claims and the U.S. Court of Appeals for the Federal Circuit.


Representative Experience:

  • Represented Biogen in a Hatch-Waxman litigation involving twenty-eight companies seeking FDA approval to market generic versions of Tecfidera®.
  • Represented Ferring in inventorship litigation, relating to desmopressin pharmaceutical compositions, acting as co-lead counsel at trial.
  • Represented Otsuka in 24 related Hatch-Waxman litigations concerning Otsuka’s Ability® tablet products and acted as lead counsel on appeal.

 

Updated Aug 2021